Communiqués AnaptysBio, Inc.

Actions

ANAB

US0327241065

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 21:59:54 23/09/2026			Varia. 5j.	Varia. 1 janv.
50,85 ^USD	-5,69%		-4,68%	+6,79%

21/09	AnaptysBio renoue avec les bénéfices au T2 grâce à la hausse de son chiffre d'affaires ; le titre progresse après-bourse	MT
21/09	AnaptysBio, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

21/09	AnaptysBio : Annual Transition Report (Form 10-KT)	PU
21/09	Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update	GL
01/09	Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference	GL
12/05	Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update	GL
12/05	Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update	AQ
11/05	Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors	GL
04/05	Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference	GL
27/04	Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim	AQ
24/04	Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim	GL
20/04	Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations	GL
30/03	Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update	AQ
30/03	First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement	AQ
30/03	Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics	AQ
27/03	Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update	GL
27/03	First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement	GL
27/03	Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics	GL
03/03	Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results	GL
05/02	Anaptys Announces Participation at Upcoming Investor Conferences	GL
09/01	Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary	GL
06/01	Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference	GL
15/12	Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis	PR
25/11	Anaptys Announces Participation in December Investor Conferences	GL
24/11	Anaptys Announces $100 Million Stock Repurchase Plan	AQ
21/11	Anaptys Announces $100 Million Stock Repurchase Plan	GL
21/11	Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary	GL